GRAIL Corp - רווח נקי למניה (EPS TTM) GRAL
GRAIL, Inc. (GRAL) is creating a cutting-edge environment for early oncology detection by integrating the Galleri test into the general screening system. The narrow specialization in blood testing is offset by the prospect of US government programs. Revenues are based on the sale of innovative diagnostics. The 12-month YoY earnings per share growth rate on the GURU.Markets chart reflects current dynamics, where the indicator value stands at 17.90.
grail.com - פילוחים אנליטיים ומדדי מפתח (GRAL)
GRAIL, Inc. operates within an isolated product cycle where stable demand for innovation renders the business a resilient defensive asset. By analyzing the EPS trend over the last 12 months YoY, an investor assesses the rolling annual growth in earnings per share, which eliminates reporting lags and determines the real margin of safety of the company's fundamental value regardless of market volatility.
